GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Cyclically Adjusted Book per Share

Rigel Pharmaceuticals (STU:RI2A) Cyclically Adjusted Book per Share : €0.61 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was €-0.166. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.61 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Rigel Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -31.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -23.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -17.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Rigel Pharmaceuticals was -6.20% per year. The lowest was -23.30% per year. And the median was -11.40% per year.

As of today (2024-06-09), Rigel Pharmaceuticals's current stock price is €0.868. Rigel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.61. Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.42.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rigel Pharmaceuticals was 2.92. The lowest was 0.52. And the median was 1.16.


Rigel Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 1.31 1.20 0.89 0.69

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.83 0.78 0.69 0.61

Competitive Comparison of Rigel Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Rigel Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.166/131.7762*131.7762
=-0.166

Current CPI (Mar. 2024) = 131.7762.

Rigel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.389 100.560 1.820
201409 1.298 100.428 1.703
201412 1.181 99.070 1.571
201503 1.177 99.621 1.557
201506 1.018 100.684 1.332
201509 0.970 100.392 1.273
201512 0.926 99.792 1.223
201603 0.748 100.470 0.981
201606 0.694 101.688 0.899
201609 0.594 101.861 0.768
201612 0.525 101.863 0.679
201703 0.642 102.862 0.822
201706 0.500 103.349 0.638
201709 0.325 104.136 0.411
201712 0.579 104.011 0.734
201803 0.439 105.290 0.549
201806 0.635 106.317 0.787
201809 0.532 106.507 0.658
201812 0.578 105.998 0.719
201903 0.505 107.251 0.620
201906 0.413 108.070 0.504
201909 0.373 108.329 0.454
201912 0.288 108.420 0.350
202003 0.421 108.902 0.509
202006 0.332 108.767 0.402
202009 0.256 109.815 0.307
202012 0.165 109.897 0.198
202103 0.387 111.754 0.456
202106 0.331 114.631 0.381
202109 0.247 115.734 0.281
202112 0.157 117.630 0.176
202203 0.036 121.301 0.039
202206 -0.020 125.017 -0.021
202209 -0.116 125.227 -0.122
202212 -0.074 125.222 -0.078
202303 -0.130 127.348 -0.135
202306 -0.149 128.729 -0.153
202309 -0.171 129.860 -0.174
202312 -0.150 129.419 -0.153
202403 -0.166 131.776 -0.166

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Rigel Pharmaceuticals  (STU:RI2A) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.868/0.61
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rigel Pharmaceuticals was 2.92. The lowest was 0.52. And the median was 1.16.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rigel Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines